ClinicalTrials.gg
CompletedNCT01306929OPEN-HARTUpdated Feb 9, 2022Results posted

Open-label Extension Study of Pridopidine (ACR16) in the Symptomatic Treatment of Huntington Disease

A Phase 2 interventional study of pridopidine in Huntington Disease, sponsored by Prilenia. Completed. Per ClinicalTrials.gov, last updated 2022-02-09.

Sponsored by Prilenia · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
134
Allocation
Not applicable
Sex
All
01

Study summary

Huntington disease (HD) is a hereditary neurodegenerative disorder causing impairment in movement, behavioral dysfunction and dementia. The movement disorder is mainly characterized by chorea (involuntary movements) and a progressive loss of voluntary movement causing a substantial functional impairment over time. The study will assess the long-term safety of pridopidine and the treatment effects during long-term, open-label treatment.

02

Conditions studied

  • Huntington Disease

Browse trials for

Keywords

  • Huntington Disease.
03

In context

Huntington Disease

293 studies on the registry are indexed under Huntington Disease; 54 are open to participants now.

This study's enrollment of 134 is above the median of 40 across 207 interventional studies indexed under Huntington Disease.

Browse Huntington Disease studies →

Lead sponsor

Prilenia is the lead sponsor of 9 studies on the registry; 2 are open to participants now.

Of its 5 completed or terminated interventional studies of FDA-regulated products, 5 (100%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
Child (0–17), Adult (18–64), Older adult (65+)
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Subject is able to, and has provided written prior to any study related procedure.
  • Patient has completed the HART (ACR16C009) or the PRIDE-HD (TV7820- CNS-20002) studies and had remained on IMP during the full on-treatment part of the study (including de-escalated patients) or has transitioned from the Open-HART pre-virtualization study period.
  • Willing and able to take oral medication and able to comply with the study specific procedures.
  • Patient has a wireless internet connection at home (and/or applicable locations) at the first remote visit.
  • Patient has the ability to transition from in-person study visits to virtual study visits. The first remote visit (RV1) will take place within approximately 30 days after the last in-person visit.

    • Additional criteria apply, please contact the investigator for more information

Exclusion criteria

Exclusion Criteria:

  • Ongoing treatment with tetrabenazine or deutetrabenazine, seizure threshold lowering medications, or certain antipsychotics and antidepressants.
  • Newly instigated or changed treatment with neuroleptics/antipsychotics
  • Use of tricyclic antidepressants or class I \& III antiarrhythmics at any time during the study period.
  • Severe intercurrent illness that, in the opinion of the Investigator (or qualified designee), may put the subject at risk when continuing participation in the study.
  • Alcohol and/or drug abuse as defined by the Diagnostic and Statistical Manual - Fourth Edition - Text Revision criteria for substance abuse - this includes the illicit use of cannabis.
  • Subjects with a known history of epilepsy or a history of febrile seizure(s) or seizure(s) of unknown cause.
  • Females who are pregnant or lactating.
  • Females who are of child bearing potential and not taking adequate precautions (either oral, barrier or chemical contraceptives) are excluded from the trial. Females of child bearing potential taking acceptable contraceptive precautions can be included.
  • Known allergy to any ingredients of the trial medication.

    • Additional criteria apply, please contact the investigator for more information
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
134 participants (actual)

Study arms

  • Experimental
    pridopidine

    45mg bid

    Drug: pridopidine

Interventions

06

What researchers measure

Primary outcomes

  1. Number of Patients With at Least One Adverse Event

    Time frame: From signing of the informed consent through the end of the follow-up period, which was defined as 30 days after the final study visit in an individual patient, an average of 2.8 years

Secondary outcomes

  1. Unified Huntington's Disease Rating Scale (UHDRS) Total Motor Score (TMS)

    TMS was defined as the sum of all UHDRS motor domains ratings. The motor section of the UHDRS assesses motor features of Huntington's Disease (HD) with standardized ratings of oculo-motor function, dysarthria, chorea, dystonia, gait, and postural stability. Each of 31 assessments is rated on a scale of 0 (normal) to 4 (marked impairment) for a TMS range of 0-124.

    Time frame: Baseline and at Month 12, 24, 36, 48, 60, and 72

07

Results

Posted Feb 9, 2022
Limitations and caveats
The study was stopped at Sponsor discretion/request; last patient last visit was 5 Jan 2018.

Participant flow

The study recruited adult patients with Huntington's Disease (HD) who had completed studies ACR16C009 (NCT00724048) or TV7820-CNS-20002 (NCT02006472). The first patient was recruited on 24 Mar 2011, and the last patient completed the trial on 5 Jan 2018.

Participant flow — Overall Study
MilestonePridopidine
Started134
Completed40
Not completed94
Withdrew: Withdrawal by subject23
Withdrew: Adverse event21
Withdrew: Physician decision13
Withdrew: Death8
Withdrew: Withdrawal by parent/guardian5
Withdrew: Protocol violation3
Withdrew: Non-compliance with study drug2
Withdrew: Lost to follow-up2
Withdrew: Various17

Outcome measures

PrimaryNumber of Patients With at Least One Adverse Event
Time frame:
From signing of the informed consent through the end of the follow-up period, which was defined as 30 days after the final study visit in an individual patient, an average of 2.8 years
Reported as:
Count of participants · Participants
Number of Patients With at Least One Adverse Event
ParticipantsPridopidine
Number of Patients With at Least One Adverse Event119
SecondaryUnified Huntington's Disease Rating Scale (UHDRS) Total Motor Score (TMS)

TMS was defined as the sum of all UHDRS motor domains ratings. The motor section of the UHDRS assesses motor features of Huntington's Disease (HD) with standardized ratings of oculo-motor function, dysarthria, chorea, dystonia, gait, and postural stability. Each of 31 assessments is rated on a scale of 0 (normal) to 4 (marked impairment) for a TMS range of 0-124.

Time frame:
Baseline and at Month 12, 24, 36, 48, 60, and 72
Reported as:
Mean · score on a scale
Unified Huntington's Disease Rating Scale (UHDRS) Total Motor Score (TMS)
score on a scalePridopidine
Baseline38.3 ± 15.2
Month 1241.5 ± 18.7
Month 2441.7 ± 20.7
Month 3644.7 ± 19.8
Month 4845.3 ± 19.7
Month 6045.7 ± 20.6
Month 7250.0 ± 23.2

Adverse events

Collected over From signing of the informed consent through the end of the follow-up period, which was defined as 30 days after the final study visit in an individual patient, an average of 2.8 years. Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Pridopidine8/134 (6%)31/134 (23.1%)119/134 (88.8%)
Most frequent serious events
Showing 10 of 57
Most frequent serious events
EventPridopidine
FallInjury, poisoning and procedural complications4/134
Subdural haematomaInjury, poisoning and procedural complications4/134
Pneumonia aspirationRespiratory, thoracic and mediastinal disorders3/134
DysphagiaGastrointestinal disorders2/134
Skull fractureInjury, poisoning and procedural complications2/134
ConvulsionNervous system disorders2/134
Loss of consciousnessNervous system disorders2/134
Subarachnoid haemorrhageNervous system disorders2/134
AgitationPsychiatric disorders2/134
DepressionPsychiatric disorders2/134
Most frequent other events
Showing 10 of 333
Most frequent other events
EventPridopidine
FallInjury, poisoning and procedural complications46/134
Weight decreasedInvestigations30/134
AnxietyPsychiatric disorders27/134
InsomniaPsychiatric disorders24/134
DepressionPsychiatric disorders20/134
ContusionInjury, poisoning and procedural complications18/134
LacerationInjury, poisoning and procedural complications18/134
ChoreaNervous system disorders18/134
DiarrhoeaGastrointestinal disorders16/134
NasopharyngitisInfections and infestations16/134

Baseline characteristics

Age, Continuous
Age, Continuous(years)Pridopidine
Mean52.4 ± 9.98
Sex: Female, Male
Sex: Female, Male(Participants)Pridopidine
Female67
Male67
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Pridopidine
American Indian or Alaska Native0
Asian0
Native Hawaiian or Other Pacific Islander0
Black or African American3
White129
More than one race0
Unknown or Not Reported2
Region of Enrollment
Region of Enrollment(participants)Pridopidine
Canada50
United States84
Weight
Weight(kg)Pridopidine
Mean74.7 ± 18.6
08

Study locations

No study locations are listed for this record.

09

References and documents

Publications

  • McGarry A, Auinger P, Kieburtz K, Geva M, Mehra M, Abler V, Grachev ID, Gordon MF, Savola JM, Gandhi S, Papapetropoulos S, Hayden M. Additional Safety and Exploratory Efficacy Data at 48 and 60 Months from Open-HART, an Open-Label Extension Study of Pridopidine in Huntington Disease. J Huntingtons Dis. 2020;9(2):173-184. doi: 10.3233/JHD-190393. PubMed 32508327 ↗
  • McGarry A, Kieburtz K, Abler V, Grachev ID, Gandhi S, Auinger P, Papapetropoulos S, Hayden M. Safety and Exploratory Efficacy at 36 Months in Open-HART, an Open-Label Extension Study of Pridopidine in Huntington's Disease. J Huntingtons Dis. 2017;6(3):189-199. doi: 10.3233/JHD-170241. PubMed 28826192 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: No

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Mar 2011 to primary completion in Jan 2018, 81 months.

Results were first posted in Feb 2022, 4 years 1 month after primary completion.

Of 22 phase 2 interventional studies under Huntington Disease, half reached primary completion within 31 months of starting (the median), counting those still running; a quarter within 21 and three quarters within 40. This study's 81 months is above that.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 28, 2011
First posted
Mar 2, 2011
StartActual
Mar 24, 2011
Primary completionActual
Jan 5, 2018
CompletionActual
Jan 5, 2018
Results first posted
Feb 9, 2022
Last update
Feb 9, 2022
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Feb 9, 2022, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT01306929
Lead sponsor
Prilenia
Responsible party
Sponsor
First posted
Mar 2, 2011
Start date
Mar 24, 2011
Primary completion
Jan 5, 2018
Completion
Jan 5, 2018
Results posted
Feb 9, 2022
Last update
Feb 9, 2022

Study contacts

See Central Contact section for questions about
principal investigator · study officials

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jan 2022. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Pridopidine

Start the discussion